Search
Folitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalCoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer. … ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).
Bismuth subgallate
go.drugbank.com/drugs/DB13909ApprovedIt is a heavy metal salt of gallic acid that is highly insoluble and poorly absorbed. … internal deodorant where it is often employed as the primary active ingredient.
Olmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigationalThe angiotensin II receptor blocker (ARB) family of drugs unique in that it blocks all angiotensin II activity, regardless of where or how it was synthesized. … However, this does not prevent the formation of all angiotensin II within the body.
Categories: Angiotensin II receptor antagonists, Angiotensin II receptor blockers (ARBs), plainSilicon
go.drugbank.com/drugs/DB12982ApprovedSilicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or … Stage II Mycosis Fungoides).
Mixtures: Procosa II, Calcium With Mg Zn Mn Cu CR Si and Vit. C & DIvabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalIvabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate … Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the
Flibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalFlibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. … in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.
Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-Oxyquinoline
go.drugbank.com/drugs/DB11145ApprovedInvestigationalVet approvedIt is used as a stabilizer for hydrogen peroxide, where it is sometimes added in cosmetic products. … Oxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and pesticide properties.
Mixtures: INDIO (111-IN) OSSINA CURIUM NETHERLANDS, Sulpak IIEntrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.
Synonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamideIbrexafungerp
go.drugbank.com/drugs/DB12471Approved[A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity. … [A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349]